JAB-8263
Small molecule
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Non-Small Cell Lung Cancer · Phase 1/2Myelofibrosis
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Myelofibrosis: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| JAB-8263: this drug | Stage not on record | Small molecule | BET bromodomain proteins (e.g. BRD4) | not yet graded | No reviewed efficacy summary in this indication | |
| Ruxolitinib (Jakafi) | Approved | Small molecule | JAK1/2 | Partial signal | NCT00934544: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48 (Baseline, Week 48): Ruxolitinib 28.5 Percentage of Participants | Best Available Therapy (BAT) 0 Percentage of Participants NCT00952289: Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24 (Baseline and Week 24): Ruxolitinib 65 participants | Placebo 1 participants | |
| Jaktinib (Zepuping) | Phase 3 | Small molecule | JAK1/2/3 | not yet graded | No reviewed efficacy summary in this indication | |
| Ropeginterferon Alfa-2b (Besremi) | Phase 3 | Protein / enzyme therapeutic | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Selinexor | Phase 3 | Small molecule | XPO1 (exportin-1) | Partial signal | NCT04562389: Co-primary endpoints at week 24: SVR35 50% with selinexor plus ruxolitinib vs 28% with ruxolitinib alone (significant); Abs-TSS not met (2026-03-24). |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow JAB-8263 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.